Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: Immunotherapeutic implications

Journal of Cellular Physiology

Volumn 226, Issue 10, 2011, Pages 2595-2600

  Calabrò, Luana ^a   Sigalotti, Luca ^b   Fonsatti, Ester ^a   Bertocci, Erica ^a   Di Giacomo, Anna Maria ^a   Danielli, Riccardo ^a,b   Cutaia, Ornella ^a   Colizzi, Francesca ^b   Covre, Alessia ^a,b   Mutti, Luciano ^c   Natali, Pier Giorgio ^d   Maio, Michele ^a,b  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c Department of General Medicine   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BETA ACTIN; MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN B7 H3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FLOW CYTOMETRY; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; MESOTHELIOMA; MESOTHELIUM CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TISSUE MICROARRAY; TUMOR BIOPSY; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CANCER VACCINES; CELL LINE, TUMOR; EPITHELIAL CELLS; HUMANS; IMMUNOPHENOTYPING; MESOTHELIOMA; NEUROBLASTOMA; PLEURAL EFFUSION; PLEURAL NEOPLASMS; RECEPTORS, IMMUNOLOGIC;

EID: 79960679811     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22600     Document Type: Article

References (42)

1. Ak G, Metintas S, Metintas M, Yildirim H, Erginel S, Kurt E, Alatas F, Cadirci O. 2009. Prognostic factors according to the treatment schedule in malignant pleural mesothelioma. J Thorac Oncol 4: 1425-1430.
2. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A. 2008. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14: 3044-3051.
3. Calabrò L, Fonsatti E, Altomonte M, Pezzani L, Colizzi F, Nanni P, Gattei V, Sigalotti L, Maio M. 2005. Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: Immunotherapeutic implications. J Cell Physiol 202: 474-477.
4. Castagneto B, Zai S, Mutti L. 2001. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II on 31 consecutive patients. Lung Cancer 31: 303-310.
5. Castriconi R, Dondero A, Augugliaro R, Cantoni C, Carnemolla B, Sementa AR, Negri F, Conte R, Corrias MV, Moretta L, Moretta A, Bottino C. 2004. Identification of 4Ig-B 7-3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA 101: 12640-12645.
6. Chapoval AL, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, Chen L. 2001. B7-H3 a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2: 269-274.
7. Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, Blute ML, Sebo TJ, Tindall DJ, Kwon ED, Karnes RJ. 2009. Expression of immunosuppressive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res 15: 2174-2179.
8. Chen Y, Tekle C, Fodstad O. 2008. The immunoregulatory protein human B7-H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr Cancer Drug Targets 8: 404-413.
9. Collins M, Ling V, Carreno B. 2005. The B7 family of immune-regulatory ligands. Genome Biol 6: 223-229.
10. Coral S, Sigalotti L, Gasparollo A, Cattarossi I, Visintin A, Cattelan A, Altomonte M, Maio M. 1999. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). J Immunother 22: 16-24.
11. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED. 2008. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 14: 5150-5157.
12. Fonsatti E, Hugues JMN, Sigalotti L, Calabrò L, Pezzani L, Colizzi F, Altomonte M, Guidoboni M, Marincola FM, Maio M. 2007. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: Immunotherapeutic implications. Clin Cancer Res 13: 3333-3338.
13. Fukushima A, Sumi T, Fukuda K, Kumagai N, Nishida T, Yamazaki T, Akiba H, Okumura K, Yagita H, Ueno H. 2007. B7-H3 regulates the development of experimental allergic conjunctivitis in mice. Immunol Lett 113: 52-57.
14. Greenwald RJ, Freeman GJ, Sharpe AH. 2005. The B7 family revisited. Annu Rev Immunol 23: 515-548.
15. Gregorio A, Corrias MM, Castriconi R, Dondero A, Mosconi M, Gambini C, Moretta A, Moretta L, Bottino C. 2008. Small round blue cell tumours: Diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule. Histopathology 53: 73-80.
16. Hashiguchi M, Kobori H, Ritprajak P, Kamimura Y, Kozono H, Azuma M. 2008. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci USA 30: 10495-10500.
17. Hassan R, Ho M. 2008. Mesothelin targeted cancer immunotherapy. Eur J Cancer 44: 46-53.
18. Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, Pastan I. 2005. Humoral immune response to mesothelina in mesothelioma and ovarian cancer patients. Clin Cancer Res 11: 3814-3820.
19. Hofmeyer K, Raj A, Zang X. 2008. The contrasting role of B7-H3. Proc Natl Acad Sci USA 30: 10277-10278.
20. Lal G, Bromberg JS. 2009. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 114: 3727-3735.
21. Loos M, Hedderich D, Ottenhausen M, Giese NA, Laschinger M, Esposito I, Kleeff J, Friess H. 2009. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 9: 463-472.
22. Mutti L, Valle MT, Balbi B, Orengo AM, Lazzaro A, Alciato P, Gatti E, Betta PG, Pozzi E. 1998. Primary human mesothelioma cells express class II MHC, ICAM-1 and 7-2 and can present recall antigens to autologous blood lymphocytes. Int J Cancer 78: 740-749.
23. Orengo AM, Spoletini L, Procopio A. 1999. Establishment of four new mesothelioma cell line: Characterization by ultrastructural and immunophenotypic analysis. Eur Respir J 13: 527-534.
24. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. 1999. The European mesothelioma epidemic. Br J Cancer 12: 972-981.
25. Powell A, Creaney J, Broomfield S, Van Bruggen I, Robinson B. 2006. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer 52: 189-197.
26. Prasad DV, Nguyen T, Li Z, Yang Y, Duong J, Wang Y, Dong C. 2004. Murine B7-H3 is a negative regulator of T cells. J Immunol 173: 2500-2506.
27. Ridolfi L, Ridolfi R. 2009. Anti-CTLA-4 therapy in melanoma: Role of Ipilimumab (MDX-010). Expert Rev Dermatol 4: 199-210.
28. Robinson C, Robinson BW, Lake RA. 1998. Sera from patients with malignant mesothelioma can contain autoantibodies. Lung Cancer 20: 175-184.
29. Rosai J. 2004. Special techniques in sirgical Pathology. In: Rosai J, Ackerman L, editors. Rosai and Ackerman's surgical pathology. 9th edition, vol. 1. St. Louis: Mosby Elsevier. 45-63.
30. Roth T, Sheinin Y, Lohse C, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, Cheville JC, Sebo TJ, Kwon ED. 2007. B7-H3 ligand expression by prostate cancer: A novel marker of prognosis and potential target for therapy. Cancer Res 67: 7893-7900.
31. Sigalotti L, Coral S, Altomonte M, Natali L, Gaudino G, Cacciotti P, Libener R, Colizzi F, Vianale G, Martini F, Tognon M, Jungbluth A, Cebon J, Maraskovsky E, Mutti L, Maio M. 2002. Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer 86: 979-982.
32. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M. 2007. Epigenetic drugs as pleiotropic agents in cancer tratment: Biomolecular aspects and clinical applications. J Cell Physiol 212: 330-344.
33. Steinberger P, Majidic O, Derdar SV, Pfistershammer K, Kirchberger S, Klauser C, Zlabinger G, Pickl WF, Stöckl J, Knapp W. 2004. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 172: 2352-2359.
34. Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, Duncan GS, Bukczynski J, Plyte S, Elia A, Wakeham A, Itie A, Chung S, Da Costa J, Arya S, Horan T, Campbell P, Gaida K, Ohashi PS, Watts TH, Yoshinaga SK, Bray MR, Jordana M, Mak TW. 2003. The B7 family member B7-H3 preferentially down-regulates T helper type T-mediated immune response. Nat Immunol 4: 899-906.
35. Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, Wang X. 2006. B7-H3 and B7-H4 expression in non small cell lung cancer. Lung Cancer 53: 143-151.
36. Sun J, Chen LJ, Zhang GB, Jiang JT, Zhu M, Tan Y, Wang HT, Lu BF, Zhang XG. 2010. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother 59: 1163-1171.
37. Wang L, Fraser CC, Kikly K, Wells AD, Han R, Coyle AJ, Chen L, Hancock WW. 2005. B7-H3 promotes acute and chronic allograft rejection. Eur J Immunol 35: 428-438.
38. Wu CP, Jiang JT, Tan M, Zhu YB, Ji M, Xu KF, Zhao JM, Zhang GB, Zhang XG. 2006. Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol 12: 457-459.
39. Zang X, Thompson RH, Al-Ahmadie H, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. 2007. B7-H3 and B7× are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 49: 19458-19463.
40. Zang X, Sullivan PS, Soslow RA, Waltz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, Spriggs DR, Dupont J, Allison JP. 2010. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 23: 1104-1112.
41. Zhang X, Allison JP. 2007. The B7-family and cancer therapy: Costimulation and coinhibition. Clin Cancer Res 13: 5271-5279.
42. Zona A, Bruno C. 2009. Health surveillance for subjects with past exposure to asbestos: From international experience and Italian regional practices to a proposed operational model. Ann Ist Super Sanità 2: 147-161.